Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
Caution urged in Europe over summer easing
Fri June 11th - The World Health Organisation has urged caution as European countries seek to ease pandemic restrictions over the summer. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...

Simple test identifies prostate cancer 'fingerprint'

Tuesday March 10th, 2020

A simple blood test can identify the ‘fingerprint’ of prostate cancer, which could transform the way doctors monitor tumour behaviour, it was announced last night.

Researchers at UCL Cancer Institute, London, UK, used Next Generation Sequencing to establish if they could identify prostate cancer DNA in blood plasma and say their discovery represents an early circulating biomarker, which can detect when the cancer is active and spreading.

They say their findings mean the liquid biopsy could be used to monitor cancer response to treatment regularly and in real-time.

The researchers say they hope their test could eventually replace the existing prostate specific antigen test.

Dr Anjui Wu, lead author of UCL Cancer Institute, said: “Metastatic prostate cancer – the most dangerous late stage of the disease – can vary substantially in its treatment response and clinical progression.

“We urgently need biomarkers that will help us determine how far along each patient’s cancer is, to determine the best course of treatment.

“With tumour biopsies difficult to obtain, being able to identify prostate cancer DNA signatures at the earliest opportunity in blood will help monitor patients better and assist more effective treatment selection and combination.”

Writing in The Journal of Clinical Investigation, the research team describe how they investigated DNA methylation from 25 metastatic prostate cancer patients, concurrently profiled using NGS. Four healthy blood plasma samples were also analysed as a control.

The research group identified circulating tumour DNA (ctDNA) methylations and they found thousands of methylation changes specific to the prostate gland in blood samples from men with prostate cancer.

They then developed these changes into a signature for tracking prostate genetic material in blood to monitor cancer activity.

Corresponding author Professor Gert Attard, of UCL Cancer Institute, said they will test the new technique in trial patients to see if it can complement or substitute the traditional serum prostate specific antigen (PSA) for diagnosis, risk assignment and monitoring.

“We believe the increased sensitivity and additional information we derive, will significantly improve the outcomes of men with advanced prostate cancer,” he added.

Wu A, Cremaschi P, Wetterskog D et al. Genome-wide plasma DNA methylation features of metastatic prostate cancer The Journal of Clinical Investigation. 9 March 2020.

Tags: Cancer | Men's Health | UK News

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)